SCHEDULE: BlackRock Boosts Protagonist Therapeutics Stake to 13.8%

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 13.8% beneficial ownership stake in Protagonist Therapeutics, Inc. as of September 30, 2025.

Summary

• BlackRock, Inc. reported beneficial ownership of 8,575,669 shares of Protagonist Therapeutics, Inc. common stock.
• This ownership represents 13.8% of the total outstanding common stock of Protagonist Therapeutics, Inc.
• BlackRock holds sole voting power over 8,481,570 shares and sole dispositive power over 8,575,669 shares.
• The filing is an Amendment No. 7 to a previous Schedule 13G.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
• iShares Core S&P Small-Cap ETF, a BlackRock affiliate, holds an interest greater than 5% of the total outstanding common stock.

Sentiment

Score: 7

Explanation: The filing indicates a significant and sustained institutional investment by BlackRock, which is generally viewed positively as a vote of confidence in the company. While it's a disclosure of ownership rather than performance, the substantial stake suggests a favorable long-term view from a major investor.

Positives

• Increased institutional ownership by a major asset manager like BlackRock can signal confidence in Protagonist Therapeutics' long-term prospects.
• A 13.8% stake indicates a significant commitment from BlackRock, potentially attracting further institutional interest.

Future Outlook

The filing does not provide any forward-looking statements or guidance regarding Protagonist Therapeutics' future performance or BlackRock's future investment intentions beyond the current ownership disclosure.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §§ 240.14a-11."

Industry Context

Large institutional investors like BlackRock frequently adjust their holdings in publicly traded companies, particularly in sectors like biotechnology (where Protagonist Therapeutics operates), based on market conditions, company performance, and strategic outlook. Significant stakes by such investors can influence market perception and liquidity for smaller-cap companies.

Stakeholder Impact

• Shareholders: Increased institutional ownership may lead to greater investor confidence and potentially improved stock liquidity.
• Company Management: A large institutional holder like BlackRock may exert influence through voting power, though the filing states the shares are not held for control purposes.

Key Dates

Recommendation

The filing reveals a substantial and continued institutional stake by BlackRock, a leading asset manager, in Protagonist Therapeutics. This significant ownership (13.8%) suggests a strong vote of confidence from a major investor, which can be a positive signal for the company's long-term prospects. While a Schedule 13G filing alone does not provide operational or financial performance data to warrant a 'buy' or 'sell' recommendation, the increased institutional interest supports a 'hold' position for existing investors, indicating stability and potential for future growth as perceived by a sophisticated market participant.

Keywords

Protagonist Therapeutics, BlackRock, Schedule 13G, Institutional Ownership, Common Stock, PTGX, Beneficial Ownership, Investment